ArticleFrontiers in pediatrics2019
Successful Treatment With Omalizumab in a Child With Asthma and Urticaria: A Clinical Case Report.
Article in Frontiers in pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety of biologics for the treatment of asthma in children and adolescents: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Sex, Allergic Diseases and Omalizumab.Biomedicines · 2022Review
- Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.Journal of asthma and allergy · 2021Review
- Sex and Gender Influences on Cancer Immunotherapy Response.Biomedicines · 2020Review
- Osteoporosis in Skin Diseases.International journal of molecular sciences · 2020Review
- Sex and Gender Aspects for Patient Stratification in Allergy Prevention and Treatment.International journal of molecular sciences · 2020Review
- New Perspectives in Food Allergy.International journal of molecular sciences · 2020Review
- Does Allergy Break Bones? Osteoporosis and Its Connection to Allergy.International journal of molecular sciences · 2020Review
- IL-33/Vitamin D Crosstalk in Psoriasis-Associated Osteoporosis.Frontiers in immunology · 2020Review
- Food Allergies and Ageing.International journal of molecular sciences · 2019Review
- Solar Urticaria, a Disease with Many Dark Sides: Is Omalizumab the Right Therapeutic Response? Reflections from a Clinical Case Report.Open medicine (Warsaw, Poland) · 2019Article
- Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood urticaria is not rare, although its persistence is less frequent. In children, chronic spontaneous urticaria (CSU) is associated with comorbidities, including asthma, allergic rhinitis, or atopic dermatitis, and many children with CSU have a family history of atopy. The therapeutic approach to CSU in children is the same one recommended by international guidelines for treatment of chronic urticaria in adults. In the European Union, according to the European Medicine Agency, omalizumab is the add-on drug of choice for the management of CSU in adult and adolescent patients (from 12 years of age) with inadequate response to H1 antihistamine therapy. In addition, in children (6 to <12 years of age), it is the add-on therapy of choice to improve asthma control. The management of children with urticaria under 12 is a therapeutic area with few certainties, where omalizumab can be administered only "off-label."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.